OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Maria Soler Nunez appointed as Chief Quality Officer
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Reinforcing commitment to ethical and sustainable growth
The agreement complements other PPAs for Sandoz production sites globally
Subscribe To Our Newsletter & Stay Updated
